Article
Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.
Oncogene - 1 Apr 2022
Sala Margaux, Allain Nathalie, Moreau Mélanie, Jabouille Arnaud, Henriet Elodie, Abou-Hammoud Aya, Uguen Arnaud, Di-Tommaso Sylvaine, Dourthe Cyril, Raymond Anne-Aurélie, Dupuy Jean-William, Gerard Emilie, Dugot-Senant Nathalie, Rousseau Benoit, Merlio Jean-Phillipe, Pham-Ledart Anne, Vergier Béatrice, Tartare-Deckert Sophie, Moreau Violaine, Saltel Frédéric
Abstract excerpt
Combined therapy with anti-BRAF plus anti-MEK is currently used as first-line treatment of patients with metastatic melanomas harboring the somatic BRAF V600E mutation. However, the main issue with targeted therapy is the acquisition of tumor cell resistance. In a majority of resistant melanoma cells, the resistant process consists in epithelial-to-mesenchymal transition (EMT). This process called phenotype...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.